

Chromosomal Microarray Analysis (CMA)

Last Review Date: October 12, 2018

Number: MG.MM.LA.36aC2

Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, ("EmblemHealth") has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated and GHI HMO Select, related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definition

Chromosomal Microarray Analysis (CMA) is a high-resolution whole-genome diagnostic tool which detects genomic copy number variations (CNVs). CNVs are chromosomal imbalances that result from the deletion and/or duplication of one or more sections of DNA. CMA is used in postnatal settings to diagnose individuals with congenital anomalies, unexplained developmental delay (DD), autism spectrum disorder (ASD) or intellectual disability (intellectual developmental delay); and in prenatal settings for miscarried fetuses and still births.

CMA which is also known as cytogenomic microarray analysis encompasses two different laboratory techniques, comparative genomic hybridization (aCGH) and single nucleotide polymorphism (SNP) arrays.

Related Guidelines

[Genetic Counseling and Testing](#)

Guideline

1. CMA genetic testing is considered medically necessary for the evaluation of a fetus when **ANY** of the following criteria are met:
 - a. Abnormal fetal anatomic findings characteristic of a genetic abnormality and detected on fetal ultrasound or fetal magnetic resonance imaging
 - b. Analyses of stillbirths with congenital anomalies or in stillbirths in which karyotype results cannot be obtained
 - c. In patients with a structurally normal fetus undergoing invasive prenatal diagnostic testing
 - d. The individual is considered at high risk for fetal aneuploidy due to ANY of the following:
 - i. The expectant mother has a history of a prior pregnancy with a trisomy
 - ii. The expectant mother will be 35 years or older at the time of delivery
 - iii. The expectant mother has a positive first or second-trimester standard biomarker screening test

2. CMA genetic testing is considered medically necessary for diagnosing developmental delay (DD), intellectual disability (ID) or autism spectrum disorder (ASD) in children when **ALL** of the following criteria are met:
 - a. A negative biochemical test for metabolic diseases, if indicated by the clinical presentation
 - b. A negative targeted genetic test, (for example: FMR1 gene analysis for Fragile X), if or when indicated by the clinical and family history
 - c. The member's clinical presentation is not specific to a well-delineated genetic syndrome
 - d. Congenital anomalies, birth defects and anatomic malformations not part of a recognizable genetic or non-genetic syndrome
3. The results of the genetic test have the potential to impact the clinical management of the member.

Limitations/Exclusions

CMA genetic testing is considered investigational and not medically necessary for all indications when the above criteria are not met.

Revision History

11/11/16 — added congenital anomalies, birth defects and anatomic malformations not part of a recognizable genetic or non-genetic syndrome to prerequisite criteria.

Applicable Procedure Codes

81228	Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number variants (eg, bacterial artificial chromosome [BAC] or oligo-based comparative genomic hybridization [CGH] microarray analysis)
81229	Cytogenomic constitutional (genome-wide) microarray analysis; interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants for chromosomal abnormalities
81405	Molecular pathology procedure, Level 6 (eg, analysis of 6-10 exons by DNA sequence analysis, mutation scanning or duplication/deletion variants of 11-25 exons, regionally targeted cytogenomic array analysis) CPOX (coproporphyrinogen oxidase) (eg, hereditary coproporphyrinuria), full gene sequence CTSC (chymotrypsin C) (eg, hereditary pancreatitis), full gene sequence PKLR (pyruvate kinase, liver and RBC) (eg, pyruvate kinase deficiency), full gene sequence (Revision eff. 01/01/2018)
S3870	Comparative genomic hybridization (CGH) microarray testing for developmental delay, autism spectrum disorder and/or intellectual disability
88230	Tissue culture for non-neoplastic disorders; lymphocyte
88262	Chromosome analysis; count 15-20 cells, 2 karyotypes, with banding

Applicable ICD-10 Diagnosis Codes

E78.71	Barth syndrome
E78.72	Smith-Lemli-Opitz syndrome
F70 - F90.9	Mental, behavioral and neurodevelopmental disorders
G31.81	Alpers disease
G31.82	Leigh's disease
G90.1	Familial dysautonomia [Riley-Day]
H93.25	Central auditory processing disorder
O09.511 - O09.529	Supervision of elderly gravida

O35.1xx0 - O35.1xx9	Maternal care for (suspected) chromosomal abnormality in fetus
O35.2xx0 - O35.2xx9	Maternal care for (suspected) hereditary disease in fetus
P02.8	Newborn affected by other abnormalities of membranes
P02.9	Newborn affected by abnormality of membranes, unspecified
P29.30	Pulmonary hypertension of newborn
P29.38	Other persistent fetal circulation
Q00.0 - Q99.9	Congenital malformations, deformations and chromosomal abnormalities
R48.0	Dyslexia and alexia
R62.0	Delayed milestone in childhood
R62.50-R62.59	Unspecified/other lack of expected normal physiological development in childhood
R89.8	Other abnormal findings in specimens from other organs, systems and tissues
Z13.4	Encounter for screening for certain developmental disorders in childhood (deleted as of 10/01/2018)
Z13.71	Encounter for nonprocreative screening for genetic disease carrier status
Z13.79	Encounter for other screening for genetic and chromosomal anomalies
Z13.89	Encounter for screening for other disorder
Z36.0	Encounter for antenatal screening for chromosomal anomalies
Z36.1	Encounter for antenatal screening for raised alphafetoprotein level
Z36.2	Encounter for other antenatal screening follow-up
Z36.3	Encounter for antenatal screening for malformations
Z36.4	Encounter for antenatal screening for fetal growth retardation
Z36.5	Encounter for antenatal screening for isoimmunization
Z36.81	Encounter for antenatal screening for hydrops fetalis
Z36.82	Encounter for antenatal screening for nuchal translucency
Z36.83	Encounter for fetal screening for congenital cardiac abnormalities
Z36.84	Encounter for antenatal screening for fetal lung maturity
Z36.85	Encounter for antenatal screening for Streptococcus B
Z36.86	Encounter for antenatal screening for cervical length
Z36.87	Encounter for antenatal screening for uncertain dates
Z36.88	Encounter for antenatal screening for fetal macrosomia
Z36.89	Encounter for other specified antenatal screening
Z36.8A	Encounter for antenatal screening for other genetic defects
Z37.1	Single stillbirth
Z37.3	Twins, one liveborn and one stillborn
Z37.4	Twins, both stillborn
Z37.69	Other multiple births, some liveborn
Z37.7	Other multiple births, all stillborn

References

1. American College of Obstetricians and Gynecologists Committee on Genetics. Committee Opinion No. 581: the use of chromosomal microarray analysis in prenatal diagnosis. *Obstet Gynecol.* 2013; 122(6):1374-1377.
2. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. DSM-5.* American Psychiatric Association. Washington, DC.
3. Babkina N, Graham JM Jr. New genetic testing in prenatal diagnosis. *Semin Fetal Neonatal Med.* 2014; 19(3):214-219.
4. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). TEC Special Report: Array Comparative Genomic Hybridization (aCGH) for the Genetic Evaluation of Patients with Developmental Delay/Mental Retardation and Autism Spectrum Disorder. *TEC Assessments 2009*; 24: Tab 10.
5. Darilek S, Ward P, Pursley A, et al. Pre- and postnatal genetic testing by array-comparative genomic hybridization: Genetic counseling perspectives. *Genet Med.* 2008;10(1):13-18.
6. Kearney HM, South ST, Wolff DJ, et al. American College of Medical Genetics recommendations for the design and performance expectations for clinical genomic copy number microarrays intended for use in the postnatal setting for detection of constitutional abnormalities. *Genet Med.* 2011a; 13(7):676-679.
7. Manning M, Hudgins L. Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. *Genet Med.* 2010; 12(11):742-745.
8. Moeschler JB, Shevell M.; American Academy of Pediatrics Committee on Genetics. Clinical genetic evaluation of the child with mental retardation or developmental delays. *Pediatrics.* 2006; 117(6):2304-2316.
9. Reddy UM, Page GP, Saade GR, et al; for the NICHD Stillbirth Collaborative Research Network. Karyotype versus microarray testing for genetic abnormalities after stillbirth. *N Engl J Med.* 2012;367(23):2185-21
10. Schaefer GB, Mendelsohn NJ. Professional Practice and Guidelines Committee. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders. 2013; 15(5):399-407.
11. Shao L, Shaw CA, Lu XY, et al. Identification of chromosome abnormalities in subtelomeric regions by microarray analysis: A study of 5,380 cases. *Am J Med Genet A.* 2008; 146A (17):2242-2251.
12. Shen Y, Dies KA, Holm IA, et al. Clinical genetic testing for patients with autism spectrum disorders. *Pediatrics.* 2010; 125(4):e727-735.